Loading
CTPH-03 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.
AACR 2026 abstract 4438 describes CTPH-03 using an MMAE-based dual-payload format. Evidence comprises cell assays, cell-derived xenografts, rodent and monkey pharmacokinetics, and preliminary animal toxicity. The abstract describes patient-derived xenograft and IND-enabling studies as preparation. Neither the second payload identity nor human efficacy or safety can be inferred from these findings.
TROP2-directed ADC carrying an MMAE-based dual-payload combination; the other payload is not identified by the public abstract. Connects to TROP2.
1.CTPH-03's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CTPH-03" OR ABSTRACT:"CTPH-03") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CTPH-03, not a curated reading list.
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/